Response of recurrent medulloblastoma to low-dose oral etoposide

D. M. Ashley, L. Meier, T. Kerby, F. M. Zalduondo, H. S. Friedman, A. Gajjar, L. Kun, P. K. Duffner, S. Smith, D. Longee

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Purpose: The outcome for patients with recurrent medulloblastoma has historically been poor, with most patients dying of disseminated disease. Here, we report on seven patients with recurrent medulloblastoma, most heavily pretreated with a variety of chemotherapeutic agents, including parenteral etoposide (VP-16), who showed responses to the administration of repeated courses of low-dose oral VP-16. Patients and Methods: Seven patients age 4 to 16 years were treated with VP-16 after neuroradiographic and clinical evidence of tumor progression. Six had received prior irradiation. All seven had been pretreated with a variety of chemotherapeutic agents and schedules, including parenteral VP-16. VP-16 was administered orally as repeated 21-day courses at 50 mg/m2/d with a 7-day interval between courses. Evaluation consisted of neuroradiographic and clinical examination after completion of every two courses of therapy. Complete blood cell counts were performed weekly. Results: The major toxicity of oral VP-16 was hematologic, with two patients requiring platelet transfusions due to thrombocytopenia and two requiring RBC transfusions. All seven patients developed treatment- related neutropenia. Two patients were supported with granulocyte colony- stimulating factor (G-CSF) between courses. One patient developed infectious epididymitis after course 2 and required intravenous antibiotics; this illness was complicated by Clostridium difficile colitis. There was one episode of fever associated with neutropenia. There were no treatment- related deaths. Of seven patients assessed, six have demonstrated partial responses (PRs) and the remaining patient had stable disease (SD). Conclusion: This report demonstrates the activity of oral VP-16 in the treatment of a small cohort of pretreated patients with recurrent medulloblastoma. This form of administration of oral VP-16 was well tolerated and produced modest toxicity.

Original languageEnglish (US)
Pages (from-to)1922-1927
Number of pages6
JournalJournal of Clinical Oncology
Volume14
Issue number6
DOIs
StatePublished - Jan 1 1996

Fingerprint

Medulloblastoma
Etoposide
Blood Cell Count
Neutropenia
Epididymitis
Platelet Transfusion
Clostridium difficile
Granulocyte Colony-Stimulating Factor
Colitis
Therapeutics
Thrombocytopenia
Oral Administration
Appointments and Schedules
Fever

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ashley, D. M., Meier, L., Kerby, T., Zalduondo, F. M., Friedman, H. S., Gajjar, A., ... Longee, D. (1996). Response of recurrent medulloblastoma to low-dose oral etoposide. Journal of Clinical Oncology, 14(6), 1922-1927. https://doi.org/10.1200/JCO.1996.14.6.1922

Response of recurrent medulloblastoma to low-dose oral etoposide. / Ashley, D. M.; Meier, L.; Kerby, T.; Zalduondo, F. M.; Friedman, H. S.; Gajjar, A.; Kun, L.; Duffner, P. K.; Smith, S.; Longee, D.

In: Journal of Clinical Oncology, Vol. 14, No. 6, 01.01.1996, p. 1922-1927.

Research output: Contribution to journalArticle

Ashley, DM, Meier, L, Kerby, T, Zalduondo, FM, Friedman, HS, Gajjar, A, Kun, L, Duffner, PK, Smith, S & Longee, D 1996, 'Response of recurrent medulloblastoma to low-dose oral etoposide', Journal of Clinical Oncology, vol. 14, no. 6, pp. 1922-1927. https://doi.org/10.1200/JCO.1996.14.6.1922
Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A et al. Response of recurrent medulloblastoma to low-dose oral etoposide. Journal of Clinical Oncology. 1996 Jan 1;14(6):1922-1927. https://doi.org/10.1200/JCO.1996.14.6.1922
Ashley, D. M. ; Meier, L. ; Kerby, T. ; Zalduondo, F. M. ; Friedman, H. S. ; Gajjar, A. ; Kun, L. ; Duffner, P. K. ; Smith, S. ; Longee, D. / Response of recurrent medulloblastoma to low-dose oral etoposide. In: Journal of Clinical Oncology. 1996 ; Vol. 14, No. 6. pp. 1922-1927.
@article{b7658f27ef5a477eb302c1e8f8afc06d,
title = "Response of recurrent medulloblastoma to low-dose oral etoposide",
abstract = "Purpose: The outcome for patients with recurrent medulloblastoma has historically been poor, with most patients dying of disseminated disease. Here, we report on seven patients with recurrent medulloblastoma, most heavily pretreated with a variety of chemotherapeutic agents, including parenteral etoposide (VP-16), who showed responses to the administration of repeated courses of low-dose oral VP-16. Patients and Methods: Seven patients age 4 to 16 years were treated with VP-16 after neuroradiographic and clinical evidence of tumor progression. Six had received prior irradiation. All seven had been pretreated with a variety of chemotherapeutic agents and schedules, including parenteral VP-16. VP-16 was administered orally as repeated 21-day courses at 50 mg/m2/d with a 7-day interval between courses. Evaluation consisted of neuroradiographic and clinical examination after completion of every two courses of therapy. Complete blood cell counts were performed weekly. Results: The major toxicity of oral VP-16 was hematologic, with two patients requiring platelet transfusions due to thrombocytopenia and two requiring RBC transfusions. All seven patients developed treatment- related neutropenia. Two patients were supported with granulocyte colony- stimulating factor (G-CSF) between courses. One patient developed infectious epididymitis after course 2 and required intravenous antibiotics; this illness was complicated by Clostridium difficile colitis. There was one episode of fever associated with neutropenia. There were no treatment- related deaths. Of seven patients assessed, six have demonstrated partial responses (PRs) and the remaining patient had stable disease (SD). Conclusion: This report demonstrates the activity of oral VP-16 in the treatment of a small cohort of pretreated patients with recurrent medulloblastoma. This form of administration of oral VP-16 was well tolerated and produced modest toxicity.",
author = "Ashley, {D. M.} and L. Meier and T. Kerby and Zalduondo, {F. M.} and Friedman, {H. S.} and A. Gajjar and L. Kun and Duffner, {P. K.} and S. Smith and D. Longee",
year = "1996",
month = "1",
day = "1",
doi = "10.1200/JCO.1996.14.6.1922",
language = "English (US)",
volume = "14",
pages = "1922--1927",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Response of recurrent medulloblastoma to low-dose oral etoposide

AU - Ashley, D. M.

AU - Meier, L.

AU - Kerby, T.

AU - Zalduondo, F. M.

AU - Friedman, H. S.

AU - Gajjar, A.

AU - Kun, L.

AU - Duffner, P. K.

AU - Smith, S.

AU - Longee, D.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Purpose: The outcome for patients with recurrent medulloblastoma has historically been poor, with most patients dying of disseminated disease. Here, we report on seven patients with recurrent medulloblastoma, most heavily pretreated with a variety of chemotherapeutic agents, including parenteral etoposide (VP-16), who showed responses to the administration of repeated courses of low-dose oral VP-16. Patients and Methods: Seven patients age 4 to 16 years were treated with VP-16 after neuroradiographic and clinical evidence of tumor progression. Six had received prior irradiation. All seven had been pretreated with a variety of chemotherapeutic agents and schedules, including parenteral VP-16. VP-16 was administered orally as repeated 21-day courses at 50 mg/m2/d with a 7-day interval between courses. Evaluation consisted of neuroradiographic and clinical examination after completion of every two courses of therapy. Complete blood cell counts were performed weekly. Results: The major toxicity of oral VP-16 was hematologic, with two patients requiring platelet transfusions due to thrombocytopenia and two requiring RBC transfusions. All seven patients developed treatment- related neutropenia. Two patients were supported with granulocyte colony- stimulating factor (G-CSF) between courses. One patient developed infectious epididymitis after course 2 and required intravenous antibiotics; this illness was complicated by Clostridium difficile colitis. There was one episode of fever associated with neutropenia. There were no treatment- related deaths. Of seven patients assessed, six have demonstrated partial responses (PRs) and the remaining patient had stable disease (SD). Conclusion: This report demonstrates the activity of oral VP-16 in the treatment of a small cohort of pretreated patients with recurrent medulloblastoma. This form of administration of oral VP-16 was well tolerated and produced modest toxicity.

AB - Purpose: The outcome for patients with recurrent medulloblastoma has historically been poor, with most patients dying of disseminated disease. Here, we report on seven patients with recurrent medulloblastoma, most heavily pretreated with a variety of chemotherapeutic agents, including parenteral etoposide (VP-16), who showed responses to the administration of repeated courses of low-dose oral VP-16. Patients and Methods: Seven patients age 4 to 16 years were treated with VP-16 after neuroradiographic and clinical evidence of tumor progression. Six had received prior irradiation. All seven had been pretreated with a variety of chemotherapeutic agents and schedules, including parenteral VP-16. VP-16 was administered orally as repeated 21-day courses at 50 mg/m2/d with a 7-day interval between courses. Evaluation consisted of neuroradiographic and clinical examination after completion of every two courses of therapy. Complete blood cell counts were performed weekly. Results: The major toxicity of oral VP-16 was hematologic, with two patients requiring platelet transfusions due to thrombocytopenia and two requiring RBC transfusions. All seven patients developed treatment- related neutropenia. Two patients were supported with granulocyte colony- stimulating factor (G-CSF) between courses. One patient developed infectious epididymitis after course 2 and required intravenous antibiotics; this illness was complicated by Clostridium difficile colitis. There was one episode of fever associated with neutropenia. There were no treatment- related deaths. Of seven patients assessed, six have demonstrated partial responses (PRs) and the remaining patient had stable disease (SD). Conclusion: This report demonstrates the activity of oral VP-16 in the treatment of a small cohort of pretreated patients with recurrent medulloblastoma. This form of administration of oral VP-16 was well tolerated and produced modest toxicity.

UR - http://www.scopus.com/inward/record.url?scp=8944252806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8944252806&partnerID=8YFLogxK

U2 - 10.1200/JCO.1996.14.6.1922

DO - 10.1200/JCO.1996.14.6.1922

M3 - Article

C2 - 8656261

AN - SCOPUS:8944252806

VL - 14

SP - 1922

EP - 1927

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -